279 related articles for article (PubMed ID: 19436655)
1. Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil.
Ferrario C
Vasc Health Risk Manag; 2009; 5(1):301-14. PubMed ID: 19436655
[TBL] [Abstract][Full Text] [Related]
2. Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil.
Mason RP
Vasc Health Risk Manag; 2011; 7():405-16. PubMed ID: 21796255
[TBL] [Abstract][Full Text] [Related]
3. Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor.
Hasler C; Nussberger J; Maillard M; Forclaz A; Brunner HR; Burnier M
Clin Pharmacol Ther; 2005 Nov; 78(5):501-7. PubMed ID: 16321616
[TBL] [Abstract][Full Text] [Related]
4. Effects of olmesartan medoxomil, an angiotensin II type 1 receptor antagonist, on plasma concentration of B-type natriuretic peptide, in hypertensive patients with type 2 diabetes mellitus: a preliminary, observational, open-label study.
Kawai T; Takei I; Shimada A; Hirata T; Tanaka K; Saisho Y; Irie J; Horimai C; Matsumoto H; Itoh H
Clin Drug Investig; 2011; 31(4):237-45. PubMed ID: 21184621
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacological profiles and clinical effects of olmesartan medoxomil, a novel angiotensin II receptor blocker].
Sada T; Mizuno M
Nihon Yakurigaku Zasshi; 2004 Oct; 124(4):257-69. PubMed ID: 15467259
[TBL] [Abstract][Full Text] [Related]
6. The protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (The VIOS study): rationale and baseline characteristics.
Smith RD; Yokoyama H; Averill DB; Cooke L; Brosnihan KB; Schiffrin EL; Ferrario CM
Am J Cardiovasc Drugs; 2006; 6(5):335-42. PubMed ID: 17083268
[TBL] [Abstract][Full Text] [Related]
7. Olmesartan medoxomil: current status of its use in monotherapy.
Brunner HR
Vasc Health Risk Manag; 2006; 2(4):327-40. PubMed ID: 17323586
[TBL] [Abstract][Full Text] [Related]
8. Olmesartan medoxomil: an angiotensin II-receptor blocker.
Brousil JA; Burke JM
Clin Ther; 2003 Apr; 25(4):1041-55. PubMed ID: 12809956
[TBL] [Abstract][Full Text] [Related]
9. Blood pressure variability, impaired autonomic function and vascular senescence in aged spontaneously hypertensive rats are ameliorated by angiotensin blockade.
Sueta D; Koibuchi N; Hasegawa Y; Toyama K; Uekawa K; Katayama T; Ma M; Nakagawa T; Waki H; Maeda M; Ogawa H; Kim-Mitsuyama S
Atherosclerosis; 2014 Sep; 236(1):101-7. PubMed ID: 25016364
[TBL] [Abstract][Full Text] [Related]
10. Olmesartan medoxomil: a review of its use in the management of hypertension.
Scott LJ; McCormack PL
Drugs; 2008; 68(9):1239-72. PubMed ID: 18547134
[TBL] [Abstract][Full Text] [Related]
11. Olmesartan medoxomil-based antihypertensive therapy evaluated by ambulatory blood pressure monitoring: efficacy in high-risk patient subgroups.
Chrysant SG; Germino FW; Neutel JM
Am J Cardiovasc Drugs; 2012 Dec; 12(6):375-89. PubMed ID: 23116225
[TBL] [Abstract][Full Text] [Related]
12. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
White WB; Weber MA; Sica D; Bakris GL; Perez A; Cao C; Kupfer S
Hypertension; 2011 Mar; 57(3):413-20. PubMed ID: 21282560
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study.
Barrios V; Boccanelli A; Ewald S; Girerd X; Heagerty A; Krzesinski JM; Lins R; Rodicio J; Stefenelli T; Woittiez A; Böhm M
Clin Drug Investig; 2007; 27(8):545-58. PubMed ID: 17638395
[TBL] [Abstract][Full Text] [Related]
14. Antagonizing the angiotensin II subtype 1 receptor: a focus on olmesartan medoxomil.
Nussberger J; Koike H
Clin Ther; 2004; 26 Suppl A():A12-20. PubMed ID: 15291375
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study.
Volpe M; Brommer P; Haag U; Miele C
Clin Drug Investig; 2009; 29(1):11-25. PubMed ID: 19067471
[TBL] [Abstract][Full Text] [Related]
16. Triple Combination Therapies Based on Olmesartan: A Personalized Therapeutic Approach to Improve Blood Pressure Control.
Volpe M; Santolamazza C; Mastromarino V; Coluccia R; Battistoni A; Tocci G
High Blood Press Cardiovasc Prev; 2017 Sep; 24(3):255-263. PubMed ID: 28608025
[TBL] [Abstract][Full Text] [Related]
17. Effect of olmesartan medoxomil on atherosclerosis: clinical implications of the emerging evidence.
Takai S; Miyazaki M
Am J Cardiovasc Drugs; 2006; 6(6):363-6. PubMed ID: 17192125
[TBL] [Abstract][Full Text] [Related]
18. Changeover Trial of Azilsartan and Olmesartan Comparing Effects on the Renin-Angiotensin-Aldosterone System in Patients with Essential Hypertension after Cardiac Surgery (CHAOS Study).
Sezai A; Osaka S; Yaoita H; Arimoto M; Hata H; Shiono M; Sakino H
Ann Thorac Cardiovasc Surg; 2016 Jun; 22(3):161-7. PubMed ID: 27086671
[TBL] [Abstract][Full Text] [Related]
19. Clinical and experimental aspects of olmesartan medoxomil, a new angiotensin II receptor antagonist.
Yoshida K; Kohzuki M
Cardiovasc Drug Rev; 2004; 22(4):285-308. PubMed ID: 15592575
[TBL] [Abstract][Full Text] [Related]
20. Effects of angiotensin receptor blockers on ambulatory plasma Renin activity in healthy, normal subjects during unrestricted sodium intake.
Jones MR; Sealey JE; Laragh JH
Am J Hypertens; 2007 Aug; 20(8):907-16. PubMed ID: 17679042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
